

**West Virginia Medicaid PDL
Recommended Change Summary
Pharmaceutical and Therapeutics (P&T) Committee
April 23, 2025**

DRUG	CURRENT PDL STATUS	PLANNED PDL STATUS (July 1, 2025)	RECOMMENDED GRANDFATHER EXISTING USERS	COMMENTS
Androgenic Agents				
AZMIRO (testosterone cypionate) injection	New to PDL	Non-Preferred		
Antihemophilia Agents				
ALHEMO (concizumab-mtci)	New to PDL	Non-Preferred		
Antipsychotics, Atypical and Combination				
OPIPZA (aripiprazole) film, soluble	New to PDL	Non-Preferred		
Cytokine and Cell Adhesion Molecule (CAM) Antagonists				
OTULFI (ustekinumab-aauz)	New to PDL	Non-Preferred		
PYZCHIVA (ustekinumab-ttwe)	New to PDL	Preferred		
SELARSDI (ustekinumab-aekn)	New to PDL	Non-Preferred		
STEQEYMA (ustekinumab-stba)	New to PDL	Non-Preferred		
YESINTEK (ustekinumab-kfce)	New to PDL	Non-Preferred		
Immunomodulators, Atopic Dermatitis				
NEMLUVIO (nemolizumab-ilto) injection, powder	New to PDL	Non-Preferred		
Lipotropics, Other (non-statins)				
TRYNGOLZA (olezarsen)	New to PDL	Non-Preferred		
Obstructive Sleep Apnea Agents				
ZEPBOUND (tirzepatide)	New to PDL	Preferred		